BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2713 related articles for article (PubMed ID: 24277834)

  • 1. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
    Feig C; Jones JO; Kraman M; Wells RJ; Deonarine A; Chan DS; Connell CM; Roberts EW; Zhao Q; Caballero OL; Teichmann SA; Janowitz T; Jodrell DI; Tuveson DA; Fearon DT
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20212-7. PubMed ID: 24277834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance.
    Fearon DT
    Cancer Immunol Res; 2014 Mar; 2(3):187-93. PubMed ID: 24778314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.
    Gunderson AJ; Yamazaki T; McCarty K; Phillips M; Alice A; Bambina S; Zebertavage L; Friedman D; Cottam B; Newell P; Gough MJ; Crittenden MR; Van der Veken P; Young KH
    PLoS One; 2019; 14(2):e0211117. PubMed ID: 30726287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
    Sorrentino C; Miele L; Porta A; Pinto A; Morello S
    Oncotarget; 2016 Sep; 7(39):64274-64288. PubMed ID: 27590504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma.
    Kawase T; Yasui Y; Nishina S; Hara Y; Yanatori I; Tomiyama Y; Nakashima Y; Yoshida K; Kishi F; Nakamura M; Hino K
    BMC Gastroenterol; 2015 Sep; 15():109. PubMed ID: 26330349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
    Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
    Meng M; Wang W; Yan J; Tan J; Liao L; Shi J; Wei C; Xie Y; Jin X; Yang L; Jin Q; Zhu H; Tan W; Yang F; Hou Z
    Tumour Biol; 2016 Aug; 37(8):10317-27. PubMed ID: 26842926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
    Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
    J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control.
    Zhen Z; Tang W; Wang M; Zhou S; Wang H; Wu Z; Hao Z; Li Z; Liu L; Xie J
    Nano Lett; 2017 Feb; 17(2):862-869. PubMed ID: 28027646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
    Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
    Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of the fibroblast activation protein α-targeted immunotherapy strategy.
    Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP
    Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma.
    Lo A; Li CP; Buza EL; Blomberg R; Govindaraju P; Avery D; Monslow J; Hsiao M; Puré E
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.
    Kraman M; Bambrough PJ; Arnold JN; Roberts EW; Magiera L; Jones JO; Gopinathan A; Tuveson DA; Fearon DT
    Science; 2010 Nov; 330(6005):827-30. PubMed ID: 21051638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC.
    Liu J; Ouyang Y; Xia Z; Mai W; Song H; Zhou F; Shen L; Chen K; Li X; Zhuang SM; Liao J
    Cell Oncol (Dordr); 2024 Apr; 47(2):623-638. PubMed ID: 37856075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
    Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
    J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity.
    Akai M; Noma K; Kato T; Nishimura S; Matsumoto H; Kawasaki K; Kunitomo T; Kobayashi T; Nishiwaki N; Kashima H; Kikuchi S; Ohara T; Tazawa H; Choyke PL; Kobayashi H; Fujiwara T
    Br J Cancer; 2024 Jun; 130(10):1647-1658. PubMed ID: 38555315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
    Kakarla S; Chow KK; Mata M; Shaffer DR; Song XT; Wu MF; Liu H; Wang LL; Rowley DR; Pfizenmaier K; Gottschalk S
    Mol Ther; 2013 Aug; 21(8):1611-20. PubMed ID: 23732988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.
    Higashino N; Koma YI; Hosono M; Takase N; Okamoto M; Kodaira H; Nishio M; Shigeoka M; Kakeji Y; Yokozaki H
    Lab Invest; 2019 Jun; 99(6):777-792. PubMed ID: 30683902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro.
    Teichgräber V; Monasterio C; Chaitanya K; Boger R; Gordon K; Dieterle T; Jäger D; Bauer S
    Adv Med Sci; 2015 Sep; 60(2):264-72. PubMed ID: 26057860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 136.